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1. Introduction 
Fungal infections, also called mycoses, are important causes of morbidity and mortality in 
humans. Some fungal infections are endemic, and these infections are usually caused by 
fungi that are present in the environment and whose spores enter humans. Other fungal 
infections are said to be opportunistic because the causative agents cause mild or no disease 
in healthy individuals but may infect and cause severe disease in immunodeficient persons.  
The human airway is continuously open to the nonsterile environment where fungal spores 
have the potential to reach lung tissue and produce disease. In the immunocompromised 
host, many fungi, including species of fungi typically considered nonpathogenic, have the 
potential to cause serious morbidity and mortality. Over the last several decades the advent 
of the human immunodeficiency virus (HIV) epidemic and the increasing use of 
immunosuppressive drugs for serious medical conditions have dramatically increased the 
number of persons who are severely immunocompromised. In addition, the range and 
diversity of fungi that cause disease have broadened. Although Candida and Aspergillus 
species continue to be the fungal pathogens that most frequently cause invasive fungal 
disease in immunocompromised persons overall, infections due to previously uncommon 
hyaline and dematiaceous filamentous fungi are being reported with increasing frequency. 
This is significant because, despite marked advances in antifungal therapy, infections 
caused by opportunistic fungal infections (rare and emerging) continue to be associated 
with high morbidity, high mortality, and poor patient outcomes. This results from a 
combination of drug-resistant strains, lack of robust clinical studies evaluating treatments, 
and severe underlying diseases in the patient [2]. 
The principal mediators of innate immunity against fungi are neutrophils and 
macrophages. Patients with neutropenia are extremely susceptible to opportunistic fungal 
infections. Phagocytes and dendritic cells sense fungal organisms by TLRs and lectin-like 
receptors called dectins . Neutrophils presumably liberate fungicidal substances, such as 
reactive oxygen species and lysosomal enzymes, and phagocytose fungi for intracellular 
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killing. Many extracellular fungi elicit strong TH17 responses, which are driven in part by 
the activation of dendritic cells by fungal products binding to the dectin receptor and 
resulting production of TH17- inducing cytokines (IL-6, IL-23) from the dendritic cells. 
The TH17 cells stimulate inflammation, and the recruited neutrophils and monocytes 
destroy the fungi. Candida infections often start at mucosal surfaces, and cell-mediated 
immunity is believed to prevent spread of the fungi into tissues. TH1 responses are 
protective in intracellular fungal infections, such as histoplasmosis, but these responses 
may elicit granulomatous inflammation, which is an important cause of host tissue injury 
in these infections. Fungi also elicit specific antibody responses that are of protective 
value [2]. 
2. Candidiasis 
Candidiasis is caused by infection with species of the genus Candida, predominantly with 
Candida albicans. Candida species are ubiquitous fungi that represent the most common 
fungal pathogens that affect humans. The growing problem of mucosal and systemic 
candidiasis reflects the enormous increase in the number of patients at risk and the 
increased opportunity that exists for Candida species to invade tissues normally resistant to 
invasion. Candida species are true opportunistic pathogens that exploit recent technological 
advances to gain access to the circulation and deep tissues [3].  
The increased prevalence of local and systemic disease caused by these yeasts has resulted 
in numerous new clinical syndromes, the expression of which depends primarily on the 
immune status of the host. Candida species produce a wide spectrum of diseases, ranging 
from superficial mucocutaneous disease to invasive illnesses. The clinical manifestations 
may be acute, subacute or chronic to episodic. Involvement may be localized to the mouth, 
throat, skin, scalp, vagina, fingers, nails, bronchi, lungs, or the gastrointestinal tract, or 
become systemic as in septicemia, endocarditis and meningitis. In healthy individuals, 
Candida infections are usually due to impaired epithelial barrier functions and occur in all 
age groups, but are most common in the newborn and the elderly. They usually remain 
superficial and respond readily to treatment. Systemic candidiasis is usually seen in patients 
with cell-mediated immune deficiency, and those receiving aggressive cancer treatment, 
immunosuppression, or transplantation therapy.  The management of serious and life-
threatening invasive candidiasis remains severely hampered by delays in diagnosis and the 
lack of reliable diagnostic methods that allow detection of both fungemia and tissue 
invasion by Candida species [4].  
The first step in the development of a candidal infection is colonization of the 
mucocutaneous surfaces. All of the factors outlined above are associated with increased 
colonization rates. The routes of candidal invasion include (1) disruption of a colonized 
surface (skin or mucosa), allowing the organisms access to the bloodstream, and (2) 
persorption via the gastrointestinal wall, which may occur following massive colonization 
with large numbers of organisms that pass directly into the bloodstream [5].  
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Candida species are the most common cause of fungal infection in immunocompromised 
persons. Oropharyngeal colonization is found in 30-55% of healthy young adults, and 
Candida species may be detected in 40-65% of normal fecal microbiota [6, 7].  
Candida species are yeastlike fungi that can form pseudohyphae and some species can 
develop true hyphae, as Candida albicans do. For the most part, Candida species are confined 
to human and animal reservoirs; however, they are frequently recovered from the hospital 
environment, including on foods, countertops, air-conditioning vents, floors, respirators, 
and medical personnel. They are also normal commensals of diseased skin and mucosal 
membranes of the gastrointestinal, genitourinary, and respiratory tracts [8-10].  
Candida species also contain their own set of well-recognized but not well-characterized 
virulence factors that may contribute to their ability to cause infection. The main virulence 
factors include the following [11]:  
• Surface molecules that permit adherence of the organism to other structures (eg, human 
cells, extracellular matrix, prosthetic devices)  
• Acid proteases and phospholipases that involve penetration and damage of cell 
envelopes 
• Ability to convert to a hyphal form (phenotypic switching) 
As with most fungal infections, host defects also play a significant role in the development 
of candidal infections. Host defense mechanisms against Candida infection and their 
associated defects that allow infection are as follows:  
• Intact mucocutaneous barriers - Wounds, intravenous catheters, burns, ulcerations 
• Phagocytic cells -Granulocytopenia 
• Polymorphonuclear leukocytes - Chronic granulomatous disease 
• Monocytic cells -Myeloperoxidase deficiency 
• Complement -Hypocomplementemia 
• Immunoglobulins -Hypogammaglobulinemia 
• Bone marrow transplantation 
• Solid organ transplantation (liver, kidney) 
• Parenteral hyperalimentation 
• Hematologic malignancies 
• Foley catheters 
• Solid neoplasms 
• Recent chemotherapy or radiation therapy 
• Corticosteroids 
• Broad-spectrum antibiotics 
• Burns 
• Prolonged hospitalization 
• Gastrointestinal tract surgery 
• Central intravascular access devices 
• Premature birth 
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• Hemodialysis 
• Acute and chronic renal failure 
Over 200 species of Candida exist in nature; thus far, only a few species have been associated 
with disease in humans. 
• The medically significant Candida species include the following [12]:  
• C albicans, the most common species identified (50-60%)  
• Candida glabrata (previously known as Torulopsis glabrata) (15-20%)  
• C parapsilosis (10-20%)  
• Candida tropicalis (6-12%)  
• Candida krusei (1-3%)  
• Candida kefyr (< 5%)  
• Candida guilliermondi (< 5%)  
• Candida lusitaniae (< 5%)  
• Candida dubliniensis, primarily recovered from patients infected with HIV 
C glabrata and C albicans account for approximately 70-80% of Candida species recovered 
from patients with candidemia or invasive candidiasis. C glabrata has recently become very 
important because of its increasing incidence worldwide, its association with fluconazole 
resistance in up to 20% of clinical specimens, and its overall decreased susceptibility to other 
azoles and polyenes.  
C krusei is important because of its intrinsic resistance to ketoconazole and fluconazole 
(Diflucan); it is also less susceptible to all other antifungals, including itraconazole 
(Sporanox) and amphotericin B.  
Another important Candida species is C lusitaniae; although not as common as other Candida 
species, C lusitaniae is of clinical significance because it may be intrinsically resistant to 
amphotericin B, although it remains susceptible to azoles and echinocandins.  
C parapsilosis is also an important species to consider in hospitalized patients. It is especially 
common in infections associated with vascular catheters prosthetic devices. Additionally, in 
vitro analyses have shown that echinocandins have a higher minimum inhibitory 
concentration (MIC) against C parapsilosis than other Candida species. The clinical relevance 
of this in vitro finding has yet to be determined [13].  
C tropicalis has frequently been considered an important cause of candidemia in patients 
with cancer (leukemia) and in those who have undergone bone marrow transplantation.  
The diagnosis of almost any form of Candida disease requires an integration of clinical, 
epidemiological, and laboratory findings. Unfortunately, results from the routine laboratory 
studies are often nonspecific and not very helpful. Clinicians are required to act definitively 
and early based on a high index of suspicion. In the past, many patients with life-
threatening candidiasis died without receiving antifungal therapy. Systemic candidiasis 
should be suspected in patients with persistent leukocytosis and either persistent 
neutropenia or other risk factors and who remain febrile despite broad-spectrum antibiotic 
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therapy. To be effective, antifungal therapy should be provided early and empirically in 
such high-risk patients. Cultures of nonsterile sites, although not useful for establishing a 
diagnosis, may demonstrate high degrees of candidal colonization. Always consider 
positive culture results from sterile sites to be significant and evidence of infection [14].  
Candidemia and disseminated candidiasis [14, 15].  
• Blood cultures are helpful but yield positive results in only 50-60% of cases of 
disseminated infection.  
• Urinalysis may be helpful and may show either colonization or renal candidiasis.  
• The serum (1,3)β-D-glucan detection assay (Glucatell, Fungitell) is a nonculture 
assay that was approved for use in the United States in May 2004. This assay 
measures the level of β-glucan (a fungal cell wall component). In a large 
multicenter study, the assay yielded a high specificity and positive predictive value 
with highly reproducible results [15]. 
• Cultures of nonsterile sites, although not useful for establishing a diagnosis, may be 
useful for initiating antifungal therapy in patients with fever that is unresponsive to 
broad-spectrum antimicrobials. Therefore, appropriate interpretation is required. 
Positive results from blood cultures and cultures from other sterile sites always imply 
the presence of invasive disease. Positive results from sterile sites should always be 
taken as significant and should always prompt treatment.  
• Gastrointestinal, respiratory, and urinary tract cultures that are positive for Candida 
may not always represent invasive disease. However, these should be considered 
sites of colonization. 
• Species identification [14] 
• C albicans, C dubliniensis, can be identified morphologically via germ-tube 
formation (hyphae are produced from yeast cells after 2-3 h of incubation) or 
biochemical assays.  
• CHROMagar Candida allows for the presumptive identification of several Candida 
species by using color reactions in specialized media that demonstrate different 
colony colors depending on the species of Candida.  
• API20C and API32C are biochemical assays that allow for the identification of the 
different Candida species with more precision. These assays evaluate the 
assimilation of numerous carbon substrates and generate profiles used in the 
identification of different fungal species.  
• The C albicans peptide nucleic acid (PNA) fluorescence in situ hybridization (FISH) 
test can be used to identify C albicans in 24-48 hours when the probe is added to 
smears that are made directly from the blood culture bottle and followed by 
hybridization. A newer version of this test now allows for the simultaneous 
identification of either C albicans or C glabrata [16, 17]. 
• Antifungal susceptibility testing [18] 
• In vitro susceptibility testing for Candida species is now standardized using the 
Clinical Laboratory Standards Institute (CLSI) microbroth dilution (CLSI M27-A2, 
2002) or the disk diffusion (CLSI M44-P, 2003) methodology. This was formerly 
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known as the National Committee for Clinical Laboratory Standards (NCCLS) 
microbroth dilution.  
• These methods may be helpful in guiding difficult therapeutic decisions. Most of 
the difficult decisions involve antifungal-refractory oral or esophageal candidiasis 
in patients with advanced HIV disease.  
• Nonculture Candida detection assays [18-20] 
• The Candida mannan assay yields a sensitivity of 31-90% (less for non-albicans 
Candida species).  
• The Candida heat labile antigen assay yields a sensitivity of 10-71%.  
• The D-arabinitol assay yields a sensitivity of 50% but is not useful for infection with 
C krusei or C glabrata.  
• The enolase assay yields a sensitivity of 55-75%, which improves with serial testing.  
• The (1,3)β-D-glucan assay is an amebocyte lysis assay with a sensitivity of 75-100% 
and a specificity of 88-100%. It is a broad-spectrum assay that detects Aspergillus, 
Candida, Fusarium, Acremonium, and Saccharomyces species. β-D-glucan is a cell wall 
component in a wide variety of fungi and can be detected based on its ability to 
activate factor G of the horseshoe crab coagulation cascade. The Fungitell assay 
may be used in the evaluation of invasive fungal infections caused by the fungi 
mentioned above. The assay does not detect infections caused by Cryptococcus 
neoformans or Zygomycetes.  
• Molecular assays such as the polymerase chain reaction (PCR) assay and DNA 
probes are still under development and in the early investigational phases, but they 
appear promising.  
 
Figure 1. Periodic Acid-Schiff (PAS) stained section of post-mortem oesophagus showing invasion of 
blood vessel by C. albicans.  Note blastoconidia and branched pseudohyphae. (Courtesy: 
www.mycology.adelaide.edu.au) 
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The treatments used to manage Candida infections vary substantially and are based on the 
anatomic location of the infection, the patients' underlying disease and immune status, the 
patients' risk factors for infection, the specific species of Candida responsible for infection, 
and, in some cases, the susceptibility of the Candida species to specific antifungal drugs. 
There have been significant changes in the management of candidiasis in the last few years, 
particularly related to the appropriate use of echinocandins and expanded-spectrum azoles 
for candidemia, other forms of invasive candidiasis, and mucosal candidiasis [21]. These 
latest recommendations include the echinocandins caspofungin, micafungin, and 
anidulafungin, along with voriconazole and posaconazole, as well as lipid formulations of 
amphotericin B in various situations. Fluconazole is still considered a first-line agent in 
nonneutropenic patients with candidemia or suspected invasive candidiasis [22]. 
3. Cryptococosis 
Cryptococcus neoformans is an encapsulated yeast. In 1894, Busse, a pathologist, first 
described the yeast in a paper he presented to the Greifswald Medical Society. Busse 
isolated the yeast from the tibia of a 31-year-old woman, noted its resistance to sodium 
hydroxide, and published the case report that same year [23]. The following year, a surgeon 
named Buschke reported the same isolate from the same patient, thus establishing the early 
eponym of Busse-Buschke disease [24]. 
Since the initial reports, researchers have identified the diverse spectrum of host responses 
to cryptococcal infection. The responses range from a harmless colonization of the airways 
and asymptomatic infection in laboratory workers (resulting in only a positive skin test 
finding) to meningitis or disseminated disease. Although virulence in animals and, possibly, 
humans varies among strains of cryptococci, virulence probably plays a relatively small role 
in the outcome of an infection. The crucial factor is the immune status of the host. The 
importance of host immunity to the development of cryptococcosis is the single most critical 
feature of this infection from diagnosis to prognosis [25, 26].  A major pathological principle 
in understanding of cryptococcosis is that many individuals are infected with this yeast but 
their immune system controls the infection with minor and insignificant 
symptoms.  However, like tuberculosis, the yeast can persist in tissue (dormancy) for long 
periods of time to then reactivate and produce disease during an immunosuppressive 
event.  Furthermore, this reactivation scenario has been supported by recent observations 
with HIV infection progression to low CD4 counts (50-100 CD4 cells/ul) and this 
immunosuppressive lymphopenia directly linked with higher risk of cryptococcosis as the 
reduction of cell-mediated immune cells occurs [27].   
There are a series of well-known risk factors associated with cryptococcal disease.  The two 
highest risk factors are HIV infection and corticosteroid use.  The corticosteroid use as a risk 
factor incorporates most of the transplant recipients and particularly, the solid organ 
transplants with their long term corticosteroid exposure and relatively high daily doses (> 
20mg/day of prednisone) [28]. Among the other risk factors that require some discussion are 
the lymphomas/chronic leukemias and the connective tissue diseases in which most of these 
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cases are aided by corticosteroid usage.  Diabetes continues to be present in a large number 
of patients with cryptococcosis [29].   
It should be noted, however, that not all patients with cryptococcosis have an underlying 
disease.  In fact, if you exclude HIV- infected patients, approximately 20-30% of patients 
with disseminated cryptococcosis will present with no apparent underlying diseases or 
known risk factors [29].  Since the host is classically protected by a vigorous Th1 response, it 
is likely that those with no apparent underlying disease but who develop disseminated 
cryptococcosis do, in fact, have some undetected alterations in their protective immune 
responses.  A small genetic susceptibility study through identification of DNA 
polymorphisms in certain immune genes has been started [30], but clearly, further 
comprehensive studies in genetic susceptibility and immune functions will be necessary for 
us to get a true appreciation for what is really going on in the apparently normal host with 
disseminated cryptococcosis.  In fact, at times, the dysregulated immune systems and 
heterogenerous populations of patients makes this group of patients (apparently normal 
hosts)the hardest to manage since they may have late disease (prolonged disease because of 
delayed diagnosis) with either a high burden of organisms before treatment and/or prone to 
the development of a very aggressive immune reconstitution inflammatory syndrome 
(IRIS).  In this group of apparently normal hosts with cryptococcosis, it is reasonable to 
check for underlying HIV infection since it is a treatable illness and also it is probably 
reasonable to obtain a total CD4 lymphocyte count to identify patients with idiopathic CD4 
lymphocytopenia which may require prolonged antifungal suppressive therapy, although 
present data suggest that this idiopathic syndrome with cryptococcosis actually has a good 
prognosis [31]. 
The general theme of immunity for this disease is that prevention of disseminated 
cryptococcosis is controlled by an efficient cell-mediated immunity.  This fact is supported 
by many in vitro studies, animal models and all present cytokine studies in humans 
[32].  For instance, defective production of interferon gamma and TNF-alpha but not IL-10 
occurs in patients who have cryptococcosis which indicates a shifting to a predominant Th2 
host response    [33].  Furthermore, during effective treatment at the CNS site of a 
cryptococcal infection, an up-regulated Th1 response occurs as measured by higher CSF 
interferon gamma levels and lower CSF yeast counts [34].  
Much of the host issues for diagnosis and initial management of cryptococcosis are based 
around a deficiency in host responses and the risk groups identify this focus.  However, it is 
essential that clinicians realize that the total management of cryptococcosis must deal with 
the total immune dysregulation that occurs and not just its early deficiencies.  This is 
emphasized by the many pleomorphic effects of the lingering cryptococcal polysaccharide 
can have on host immune functions. Thus, even the yeast and its products can modulate the 
host environment.  This immune dysregulation was clearly identified during the AIDS 
epidemic with cryptococcosis and the use of HAART for HIV infection during 
cryptococcosis [35, 36]. 
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Cryptococcus neoformans has become a major human pathogen and a common infection in 
certain immunocompromised hosts [36]. Cryptococcosis, the disease resulting from infection 
with C. neoformans, varies from a localized skin lesion or asymptomatic colonization of the 
respiratory tree to a widely disseminated life-threatening infection, which may infect all 
organs of the body. However, C. neoformans has a special propensity for invading the central 
nervous system and cryptococcal meningoencephalitis is the primary clinical presentation 
for the life-threatening stage of this infection [37].   
Although the genus Cryptococcus contains more than 50 species, only C neoformans and 
Cryptococcus gattii are considered principal pathogens in humans. Previously, C neoformans 
was defined as having two varieties—var neoformans and var gattii. However, based on the 
elucidation of the genomic sequences, C neoformans and C gattii are now considered two 
distinct species. These two species have 5 serotypes based on antigenic specificity of the 
capsular polysaccharide; these include serotypes A, D, and AD (C neoformans) and serotypes 
B and C (C gattii). C neoformans is the most common species in temperate climates 
throughout the world and is found in aged pigeon droppings. Until recently, C gattii was 
found principally in tropical and subtropical climates. C gattii is not associated with birds 
but grows in the litter around certain species of eucalyptus trees (ie, Eucalyptus camaldulensis, 
Eucalyptus tereticornis) [38].   
Worldwide, C neoformans serotype A causes most cryptococcal infections in 
immunocompromised patients, including patients infected with HIV. For unknown reasons, 
C. gattii rarely infects persons with HIV infection and other immunosuppressed patients. 
Patients infected with C gattii are usually immunocompetent, respond slowly to treatment, 
and are at risk for developing intracerebral mass lesions (eg, cryptococcomas). Naturally 
occurring cryptococcosis occurs in both animals and humans, but neither animal-to-human 
transmission nor person-to-person respiratory transmission via the respiratory route has 
been documented. Transmission via organ transplantation has been reported when infected 
donor organs were used. C neoformans causes the vast majority of cryptococcal infections in 
immunosuppressed hosts, including patients with AIDS, whereas C gattii causes 70%-80% of 
cryptococcal infections among immunocompetent hosts [39].    
C neoformans reproduces by budding and forms round yeastlike cells that are 3-6 µm in 
diameter. Within the host and in certain culture media, a large polysaccharide capsule 
surrounds each cell. C neoformans forms smooth, convex, yellow or tan colonies on solid 
media at 20-37°C (68-98.6°F). This fungus is identified based on its microscopic appearance, 
biochemical test results, and ability to grow at 37°C (98.6°F); most nonpathogenic 
Cryptococcus strains do not grow at this temperature. In addition, C neoformans does not 
assimilate lactose and nitrates or produce pseudomycelia on cornmeal or rice-Tween agar.  
Most strains of C neoformans can use creatinine as a nitrogen source, which may partially 
explain the growth of the organism in creatinine-rich avian feces. Another useful 
biochemical characteristic of C neoformans, which distinguishes it from nonpathogenic 
strains, is its ability to produce melanin. The fungal enzyme phenol oxidase acts on certain 
substrates (eg, dihydroxyphenylalanine, caffeic acid) to produce melanin [40, 41].     
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C gattii contains genotypes VGI and the more commonly identified VGIIa and VDIIb. 
Cryptococcus species can reproduce via same-sex mating, and VGIIa may have arisen from 
the same-sex mating of VGIIb and another strain that has yet to be identified [38].    
In 1976, Kwon-Chung described the perfect (ie, sexual, teleomorphic) form of C neoformans, 
which was named Filobasidiella neoformans. Prior to the identification of F neoformans, which 
is mycelial, C neoformans was considered a monomorphic yeast. F neoformans results from the 
mating of suitable strains of serotypes A and D. The perfect state of C gattii is Filobasidiella 
bacillispora and results from the mating of serotypes B and C. Some strains of A and D can 
mate with strains of B and C [42]. 
Following inhalation, the yeast spores are deposited into the pulmonary alveoli, where they 
must survive the neutral-to-alkaline pH and physiologic concentrations of carbon dioxide 
before they are phagocytized by alveolar macrophages. Glucosylceramide synthase (GCS) 
has been identified as an essential factor in the survival of C neoformans in this extracellular 
environment.  Although GCS is a critical factor in extracellular survival of the yeast, the 
yeast no longer requires GCS to survive the intracellular, more acidic, environment within 
the macrophage once it is phagocytized by alveolar macrophages.  Unencapsulated yeast are 
readily phagocytosed and destroyed, whereas encapsulated organisms are more resistant to 
phagocytosis. The cryptococcal polysaccharide capsule has antiphagocytic properties and 
may be immunosuppressive. The antiphagocytic properties of the capsule block recognition 
of the yeast by phagocytes and inhibit leukocyte migration into the area of fungal replication 
[43].  
The host response to cryptococcal infection includes both cellular and humoral components. 
Animal models demonstrate that natural killer cells participate in the early killing of 
cryptococci and, possibly, antibody-dependent cell-mediated killing. In vitro monocyte-
derived macrophages, natural killer cells, and T lymphocytes can inhibit or kill cryptococci. 
A successful host response includes an increase in helper T-cell activity, skin test conversion, 
and a reduction in the number of viable organisms in the tissues. In addition to cellular 
mechanisms, anticryptococcal antibodies and soluble anticryptococcal factors have been 
described. Antibodies to cryptococcal antigens play a critical role in enhancing the 
macrophage- and lymphocyte-mediated immune response to the organism. Researchers 
have used monoclonal antibodies to capsular polysaccharide to passively immunize mice 
against C neoformans [44, 45].  
C neoformans infection is usually characterized by little or no necrosis or organ dysfunction 
until late in the disease. Organ damage may be accelerated in persons with heavy infections. 
The lack of identifiable endotoxins or exotoxins may be partly responsible for the absence of 
extensive necrosis early in cryptococcal infections. Organ damage is primarily due to tissue 
distortion secondary to the expanding fungal burden. Extensive inflammation or fibrosis is 
rare. The characteristic lesion of C neoformans consists of a cystic cluster of yeast with no 
well-defined inflammatory response. Well-formed granulomas are generally absent. C 
neoformans can cause an asymptomatic pulmonary infection followed later by the 
development of meningitis, which is often the first indication of disease. If limited to the 
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lungs, C neoformans infection may cause pneumonia, poorly defined mass lesions, 
pulmonary nodules, and, rarely, pleural effusion. Although immune defects are common in 
patients with meningitis or disseminated infection, patients with disease that is confined to 
the lungs are usually immunocompetent [46].  
Once cryptococcosis is considered in the differential diagnosis of an infectious disease there 
are very good tools to diagnose it.  Histopathology can be relatively distinctive with the 
capsule around the yeasts identified by alcian blue or mucicarmine stains and a Fontana-
Masson stain can identify melanin production.  These 5-20um  budding or single yeasts can 
clearly be seen in the low-cost colloidal medium of an initial India ink examination on 
cerebrospinal fluid that can be positive in up to 80% of HIV-infected patients with 
cryptococcal meningoencephalitis and with careful examination can be positive in 50% of 
non-HIV infected patients.  This is generally related to burden of yeasts and frequently 
patients with AIDS and disseminated cryptococcosis will have a large burden of yeasts in 
CSF that can range between 106-107CFU of yeasts/ml.  The India ink examination has 
difficulty in identifying yeasts when their concentrations drop to 103 CFU of yeasts/ml or 
lower.  There are some clinical cases and this is more commonly reported in the lung where 
the histopathology has some difficulty in detecting small capsules.  However, it is still likely 
that a capsule is present since an acapsular mutant is uniformly avirulent. There are a series 
of non -specific stains which might identify this yeast and particularly calcofluor and 
Gomori’s methenamine silver stains which represent classic fungal stains will identify this 
yeast in tissue.  There are culture, molecular, and antibody methods to distinguish C. 
neoformans from C. gattii but at present except for epidemiological purposes it is not clear 
that separating an isolate into specific species is a necessary requirement of the laboratory to 
help clinical management of the patient [47, 48].     
The serologies of cryptococcosis  for diagnosis have been very well studied.  Serum 
cryptococcal antibodies are not particularly helpful in diagnosing and deciding treatment 
for cryptococcosis and therefore are not used clinically.  These antibodies, however, are 
useful for epidemiological studies of exposure and their presence may actually suggest a 
good prognostic sign. On the other hand, the detection of cryptococcal capsular 
polysaccharide antigen in serum or CSF has performed extraordinarily well in diagnosis for 
many years .  It is one of the premier diagnostic tests in all of medical mycology.  There is 
also some correlation between antigen load and burden of viable yeasts in the host prior to 
treatment so the height of the antigen titer may have some prognostic features.  There are 
primarily two types of commercial tests, latex agglutination and ELISA systems.  The 
sensitivity and specificity of these tests are above 90% and although there are occasional 
false positives or false negatives, these results can frequently be sorted out with careful 
repeat testing or confirmatory culture results.  Therefore, in areas where this fungus is 
endemic, any subacute or chronic meningitis case should have a CSF cryptococcal 
polysaccharide antigen test performed.  It is rapid and accurate.  Despite its diagnostic 
utility and possessing some general prognostic features on initial titer, the cryptococcal 
antigen test is not very precise for use in following therapy.   It is a large molecule with 
many immunological effects but the exact kinetics of its elimination from the body are 
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variable and not precisely predictive of success.  All clinicians would like to see the antigen 
eliminated from the host with successful therapy but treatment decisions cannot be directly 
linked to the quantitative antigen measurement.  The term isolated cryptococcal 
polysaccharidemia describes a condition in very high-risk patients primarily those with HIV 
infection who have a positive cryptococcal antigen titer and no positive cultures or 
prominent symptoms.  In these patients the incidence of eventually developing 
cryptococcosis is very high and in most patients an examination of CSF is warranted and 
even if negative, administration of empiric antifungal therapy should be considered [49, 50].  
The use of the cryptococcal antigen in a high prevalence area such as sub-Saharan Africa as 
a screening device has great appeal if it could be cheap and easily performed.  There is now 
a Lateral Flow Test being studied and marketed which has the great potential to be cheap 
and could use finger stick blood or urine.  It is very low tech as a simple dipstick test and 
has an easy storage requirement. There are now prospective data that in those HIV-infected 
patients  that have a negative cryptococcal antigen test are unlikely to develop 
cryptococcosis over the next year.  A positive cryptococcal antigen test will need a lumbar 
puncture work up to rule out CNS disease and even with negative CNS disease but a 
positive test, it probably supports antifungal treatment until HAART returns improved host 
immunity.  This simple Lateral Flow Test could have a profound effect on new management 
strategies for the vast number of patients with this disease.  It simply needs to be integrated 
into the health care systems in resource-limited environments.  All these issues are being 
examined at present [51].     
Finally, the yeast is relatively easy to culture on standard media with growth in 2-10 days and it 
can be isolated from blood culture systems.  Although quantitative CSF yeast counts have 
excellent predictive value for therapeutic outcome in research studies, they have yet to be 
incorporated into clinical practice. In fact, future strategies should consider measurement of the 
rate of yeast decline in CSF as a judge to success of induction therapy and its length [52, 53].     
The demonstration of encapsulated yeast cells in CSF, biopsy tissue, blood or urine should 
be considered significant, even in the absence of clinical symptoms. Positive sputum 
specimens should be considered potentially significant, even though Cryptococcus may also 
occur in respiratory secretions as a saprophyte. Basically, all patients with a positive 
microscopy for cryptococci, from any site should be investigated for disseminated disease, 
especially by culture and antigen detection. 
In patients who are co-infected with HIV and C neoformans, the therapeutic goal may differ 
from that in patients with cryptococcal infection uncomplicated by HIV infection. For 
cryptococcal infections in patients with concomitant HIV infection who have a CD4 count of 
less than 200 cells/µL, the therapeutic goal is to control the acute infection, followed by life-
long suppression of C neoformans. For patients infected with HIV who have successfully 
completed an initial course of therapy, remain free of symptoms of cryptococcal disease, and 
reconstitute their CD4 count to more than 200 CD4 cells/µL for more than 6 months, some 
authorities suggest that suppressive therapy may be discontinued. However, if the patient’s 
CD4 count falls to less than 200 cells/µL, suppressive therapy should be reinstituted [54].     
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Figure 2. India ink preparation of CSF showing a typical yeast cell of C. neoformans surrounded by a 
characteristic wide gelatinous capsule.    (Courtesy: www.mycology.adelaide.edu.au) 
4. Pneumocystosis 
Pneumocystis is a genus of unicellular fungi found in the respiratory tracts of many 
mammals and humans. Distinct genomic variability exists between host-specific members of 
the genus. The organism was first described in 1909 by Chagas and then a few years later by 
Delanöes, who ultimately named the organism in honor of Dr. Carini after isolating it from 
infected rats. Years later, Dr. Otto Jirovec and his group isolated the organism from humans, 
and the organism responsible for PCP was renamed after him [55].     
The taxonomic classification of the Pneumocystis genus was debated for some time. It was 
initially mistaken for a trypanosome and then later for a protozoan. In the 1980s, 
biochemical analysis of the nucleic acid composition of Pneumocystis rRNA and 
mitochondrial DNA identified the organism as a unicellular fungus rather than a protozoan. 
Subsequent genomic sequence analysis of multiple genes including elongation factor 3, a 
component of fungi protein synthesis not found in protozoa, further supported this notion.  
The organism is found in 3 distinct morphologic stages, as follows: 
• The trophozoite (trophic form), in which it often exists in clusters 
• The sporozoite (precystic form) 
• The cyst, which contains several intracystic bodies (spores) 
Pneumocystis organisms are commonly found in the lungs of healthy individuals. Most 
children are believed to have been exposed to the organism by age 3 or 4 years, and its 
occurrence is worldwide [56]. 
Pneumocystis carinii pneumonia (PCP), as the condition is commonly termed (although the 
causative organism has been renamed Pneumocystis jiroveci, is the most common opportunistic 
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infection in persons with HIV infection. Pneumocystis first came to attention as a cause of 
interstitial pneumonia in severely malnourished and premature infants during World War II 
in Central and Eastern Europe. Before the 1980s, fewer than 100 cases of PCP were reported 
annually in the United States, occurring in patients who were immunosuppressed (eg, cancer 
patients receiving chemotherapy and solid-organ transplant recipients receiving 
immunosuppressants). In 1981, the Centers for Disease Control and Prevention reported PCP 
in 5 previously healthy homosexual men residing in the Los Angeles area [57].  
P jiroveci is now one of several organisms known to cause life-threatening opportunistic 
infections in patients with advanced HIV infection worldwide. Well over 100,000 cases of 
PCP were reported in the first decade of the HIV epidemic in the United States in people 
with no other cause for immunosuppression.  
While officially classified as a fungal pneumonia, PCP does not respond to antifungal 
treatment. Although a histopathologic demonstration of the organism is required for a 
definitive diagnosis (see Histologic Findings), treatment should not be delayed [58]. 
Treatment of PCP may be initiated before the workup is complete in severely ill high-risk 
patients. Treatment of PCP depends on the degree of illness at diagnosis, determined on the 
basis of the alveolar-arterial gradient.  Antibiotics are primarily recommended for treatment 
of mild, moderate, or severe PCP. Trimethoprim-sulfamethoxazole (TMP-SMX) has been 
shown to be as effective as intravenous pentamidine and more effective than other 
alternative treatment regimens. Corticosteroids are used as adjunctive initial therapy only in 
patients with HIV infection who have severe PCP. Preventive measures (eg, smoking 
cessation and chemoprophylaxis) can play an important role in disease management [59].  
4.1. Transmission of Pneumocystis 
Animal studies have suggested that Pneumocystis organisms are communicable; airborne 
transmission has been reported. Human evidence of this is provided by molecular analysis of 
Pneumocystis isolates obtained from groups of patients involved in hospital outbreaks [60, 61]. 
Further evidence of human transmission has been found in cases of recurrent pneumonia in 
which the genotype of Pneumocystis organisms in the same person differed in prior episodes. 
Despite this, barrier precautions are not required for patients hospitalized with P carinii 
pneumonia (PCP) except to protect other patients with depressed immunity.  
4.2. Development of PCP 
Disease occurs when both cellular immunity and humoral immunity are defective. Once 
inhaled, the trophic form of Pneumocystis organisms attach to the alveoli. Multiple host 
immune defects allow for uncontrolled replication of Pneumocystis organisms and 
development of illness. Activated alveolar macrophages without CD4+ cells are unable to 
eradicate Pneumocystis organisms. Increased alveolar-capillary permeability is visible on 
electron microscopy. 
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Physiologic changes include the following: 
• Hypoxemia with an increased alveolar-arterial oxygen gradient 
• Respiratory alkalosis 
• Impaired diffusing capacity 
• Changes in total lung capacity and vital capacity 
There have been reports of PCP occurring as part of the immune reconstitution syndrome 
[62, 63]. 
4.3. Risk factors for PCP 
PCP is caused by infection with P jiroveci. The following groups are at risk for PCP [64, 65]:  
• Persons with HIV infection whose CD4+ cells fall below 200/µL and who are not 
receiving PCP prophylaxis (In addition, in patients with HIV infection, findings of other 
opportunistic infections [eg, oral thrush] increases the risk of PCP, regardless of CD4+ 
count).  
• Persons with primary immune deficiencies, including hypogammaglobulinemia and 
severe combined immunodeficiency (SCID). 
• Persons receiving long-term immunosuppressive regimens for connective-tissue 
disorders, vasculitides, or solid-organ transplantation (eg, heart, lung, liver, kidney) 
• Persons with hematologic and nonhematologic malignancies, including solid tumors 
and lymphomas 
• Persons with severe malnutrition 
Before the widespread use of prophylaxis for P carinii pneumonia (PCP), the frequency of 
Pneumocystis infection in lung transplant patients alone was as high as 88%. Now, with the 
routine use of prophylaxis, PCP is very rare in solid-organ transplant patients and has 
significantly decreased in patients infected with HIV. Prior to the widespread use of highly 
active antiretroviral therapy (HAART), PCP occurred in 70-80% of patients with HIV 
infection. The frequency of PCP is decreasing with the use of PCP prophylaxis and HAART. 
PCP is still the most common opportunistic infection in patients with HIV infection. Patients 
with HIV infection are more prone to PCP recurrence than patients not infected with HIV.  
In developing regions of the world, the prevalence of PCP was once thought to be much 
lower, but studies have shown that the lower reported incidence is likely a failure to 
accurately diagnose PCP. An accurate diagnosis requires access to modern medical care, 
which is not available worldwide [66].  
Currently, the frequency of documented Pneumocystis infection is increasing in Africa, with 
Pneumocystis organisms found in up to 80% of infants with pneumonia who have HIV infection. 
In sub-Saharan Africa, tuberculosis is a common co-infection in persons with PCP [67]. 
A lactic dehydrogenase (LDH) study is performed as part of the initial workup. LDH levels 
are usually elevated (>220 U/L) in patients with P carinii pneumonia (PCP). They are 
elevated in 90% of patients with PCP who are infected with HIV. The study has a high 
 
Immunodeficiency 
 
164 
sensitivity (78-100%); its specificity is much lower because other disease processes can result 
in an elevated LDH level.  LDH levels appear to reflect the degree of lung injury. They 
should decline with successful treatment. Consistently elevated LDH levels during 
treatment may indicate therapy failure and a worse prognosis [68].  
Quantitative PCR for pneumocystis may become useful in distinguishing between colonization 
and active infection, but these assays are not yet available for routine clinical use [69]. 
In one study, patients with positive quantitative PCR but negative immunofluorescence for 
pneumocystis had a higher 1-year mortality but only in the context of systemic 
inflammatory conditions. There was no significant difference for patients with solid-organ 
or hematologic malignancy [70]. 
β-D-Glucan (BDG) is a cell-wall component of many fungi, including candida, aspergillus, 
and pneumocystis (but not the zygomycetes). It has been shown to be a sensitive test to 
detect PCP in a meta-analysis of 12 studies assessing the sensitivity, specificity and overall 
accuracy of the test [71]. 
5. Aspergilosis 
Aspergillus species are ubiquitous molds found in organic matter. Although more than 100 
species have been identified, the majority of human illness is caused by Aspergillus fumigatus 
and Aspergillus niger and, less frequently, by Aspergillus flavus and Aspergillus clavatus. The 
transmission of fungal spores to the human host is via inhalation [72].  
Aspergillus may cause a broad spectrum of disease in the human host, ranging from 
hypersensitivity reactions to direct angioinvasion. Aspergillus primarily affects the lungs, 
causing 4 main syndromes, including allergic bronchopulmonary aspergillosis (ABPA), 
chronic necrotizing Aspergillus pneumonia (or chronic necrotizing pulmonary aspergillosis 
[CNPA]), aspergilloma, and invasive aspergillosis. However, in patients who are severely 
immunocompromised, Aspergillus may hematogenously disseminate beyond the lung, 
potentially causing endophthalmitis, endocarditis, and abscesses in the myocardium, 
kidney, liver, spleen, soft tissue, and bone. Aspergillus is second to Candida species as a cause 
of fungal endocarditis. Aspergillus -related endocarditis and wound infections occur in the 
context of cardiac surgery [73]. 
ABPA is a hypersensitivity reaction to A fumigatus colonization of the tracheobronchial tree 
and occurs in conjunction with asthma and cystic fibrosis (CF). Allergic fungal sinusitis may 
also occur alone or with ABPA. Bronchocentric granulomatosis and malt worker's lung are 2 
hypersensitivity lung diseases that are caused by Aspergillus species, but they are rare [74]. 
An aspergilloma is a fungus ball (mycetoma) that develops in a preexisting cavity in the 
lung parenchyma. Underlying causes of the cavitary disease may include treated 
tuberculosis or other necrotizing infection, sarcoidosis, CF, and emphysematous bullae. The 
ball of fungus may move within the cavity but does not invade the cavity wall; however, it 
may cause hemoptysis [75]. 
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CNPA is a subacute process usually found in patients with some degree of 
immunosuppression, most commonly that associated with underlying lung disease, 
alcoholism, or long-term corticosteroid therapy. Because it is uncommon, CNPA often 
remains unrecognized for weeks or months and can cause a progressive cavitary pulmonary 
infiltrate [74].  
Invasive aspergillosis is a rapidly progressive, often fatal infection, associated with significant 
mortality, with a rate of 30-95%, that occurs in patients who are severely immunosuppressed, 
including those who are profoundly neutropenic, those who have received bone marrow or 
solid organ transplants, and patients with advanced AIDS or chronic granulomatous disease. 
This infectious process is characterized by invasion of blood vessels, resulting in multifocal 
infiltrates, which are often wedge-shaped, pleural-based, and cavitary. Dissemination to other 
organs, particularly the central nervous system, may occur [76]. 
Aspergillus causes a spectrum of disease, from colonization to hypersensitivity reactions to 
chronic necrotizing infections to rapidly progressive angioinvasion, often resulting in death. 
Rarely found in individuals who are immunocompetent, invasive Aspergillus infection 
almost always occurs in patients who are immunosuppressed by virtue of underlying lung 
disease, immunosuppressive drug therapy, or immunodeficiency [73]. 
Aspergillus hyphae are histologically distinct from other fungi in that the hyphae have frequent 
septae, which branch at 45° angles. The hyphae are best visualized in tissue with silver stains. 
Although many species of Aspergillus have been isolated in nature, A fumigatus is the most 
common cause of infection in humans. A flavus and A niger are less common. Likely, this 
relates to the ability of A fumigatus, but not most other Aspergillus species, to grow at normal 
human body temperature. Human host defense against the inhaled spores begins with the 
mucous layer and the ciliary action in the respiratory tract. Macrophages and neutrophils 
encompass, engulf, and eradicate the fungus. However, many species of Aspergillus produce 
toxic metabolites that inhibit macrophage and neutrophil phagocytosis. Corticosteroids also 
impair macrophage and neutrophil function. Underlying immunosuppression (eg, HIV 
disease, chronic granulomatous disease, pharmacologic immunosuppression) also contributes 
directly to neutrophil dysfunction or decreased numbers of neutrophils. In individuals who 
are immunosuppressed, vascular invasion is much more common and may lead to infarction, 
hemorrhage, and necrosis of lung tissue. Persons with CNPA typically have granuloma 
formation and alveolar consolidation. Hyphae may be observed within the granulomata [77].  
Because Aspergillus infection may cause colonization, allergy, or invasive infection, its 
manifestations are quite variable and are best considered based on the disease process. 
Allergic bronchopulmonary aspergillosis is defined by several abnormalities, including 
asthma, eosinophilia, a positive skin test result for A fumigatus, marked elevation of the 
serum immunoglobulin E (IgE) level to greater than 1000 IU/dL, fleeting pulmonary 
infiltrates, central bronchiectasis, mucoid impaction, and positive test results for Aspergillus 
precipitins (primarily immunoglobulin G [IgG], but also immunoglobulin A and 
immunoglobulin M, antibodies). Minor criteria for diagnosis include positive Aspergillus 
radioallergosorbent assay test results and culture findings for Aspergillus in sputum [74]. 
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Figure 3. Grocott’s methenamine silver (GMS) stained tissue section of lung showing fungal balls of 
hyphae of Aspergillus fumigatus.  (Courtesy: www.mycology.adelaide.edu.au) 
Diagnostic criteria for ABPA in persons with CF were revised by the Cystic Fibrosis 
Foundation. ABPA is considered a definite diagnosis requiring treatment if the following 
are noted: (1) clinical deterioration, including cough, wheeze, increased sputum production, 
diminished exercise tolerance, or diminished pulmonary function; (2) total serum IgE level 
greater than 1000 IU/mL or a greater than 2-fold rise from baseline; (3) positive serology 
results for Aspergillus (Aspergillus precipitins or Aspergillus -specific IgG or IgE); and (4) new 
infiltrates on chest radiographs or CT scans. Treatment for ABPA is also recommended in 
patients with CF who have new radiographic findings and symptoms and a change in 
baseline IgE level to greater than 500 IU/mL [79]. 
Definitive diagnosis of invasive aspergillosis or chronic necrotizing Aspergillus pneumonia 
depends on the demonstration of the organism in tissue [76]. 
In the appropriate clinical setting of pulmonary infiltrates in a patient who is neutropenic or 
immunosuppressed, visualization of the characteristic fungi using Gomori methenamine 
silver stain or Calcofluor or a positive culture result from sputum, needle biopsy, or 
bronchoalveolar lavage (BAL) fluid should result in the prompt institution of therapy. This 
is especially important after bone marrow transplantation because a positive Aspergillus 
culture result from sputum has a 95% positive predictive value for invasive disease. 
However, a negative fungus result from culture of sputum or BAL fluid does not exclude 
pulmonary aspergillosis because Aspergillus is cultured from sputum in 8-34% of patients 
and from BAL fluid in 45-62% of patients eventually found by biopsy or autopsy to have 
invasive disease [80].  
An assay to detect galactomannan, a major component of the Aspergillus cell wall, is 
available. Patients who are at high risk, such as those who have received stem cell 
transplants or who have prolonged neutropenia, may be screened for the development of 
invasive Aspergillus infection by monitoring serum galactomannan levels weekly.The 
presence of an elevated galactomannan level in BAL fluid may also be helpful in the 
diagnosis of pulmonary aspergillosis in patients in whom compatible radiographic changes 
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are present and BAL testing is performed in the suspicious area. A meta-analysis and 
systematic review determined that the measurement of BAL-galactomannan levels may help 
in diagnosing invasive aspergillosis early [81, 82].   
A study by Luong et al of 150 BAL samples from lung transplant recipients concluded that 
real-time polymerase chain reaction (PCR) assays could be useful in diagnosis of invasive 
aspergillosis in high-risk populations. Pan-Aspergillus PCR combined with BAL 
galactomannan testing was 97% specific and 93% sensitive for invasive pulmonary 
aspergillosis. Species-specific real-time PCR assays for A fumigatus and for A terreus could be 
used to rule out or identify the common A fumigatus and the amphotericin B-resistant A 
terreus [83].   
Histopathology and silver staining for persons with invasive aspergillosis demonstrates the 
characteristic septate hyphae, branching at acute angles, and acute inflammatory infiltrate 
and tissue necrosis with occasional granulomata and blood vessel invasion. The airways of 
patients with ABPA contain mucus filled with degenerating eosinophils and typical fungal 
hyphae. ABPA may occur on a background of chronic eosinophilic pneumonia and 
bronchiolitis, granulomatous bronchitis, bronchocentric granulomatosis, and, occasionally, 
BOOP [84].    
Selection of therapy also needs to consider the certainty of the diagnosis. Voriconazole, 
itraconazole, the investigational azoles with anti-mould activity, and amphotericin B all 
possess a reasonably broad-spectrum of activity against Aspergillus and the related hyaline 
moulds. Their activity does, however, vary for the agents of zygomycosis, with 
posaconazole being the azole with the most reliable activity against this class of fungi. The 
echinocandin glucan synthesis inhibitors (caspofungin, FK463, and anidulafungin) possess a 
narrower spectrum of activity and should only be used if the infection is known to be due to 
Aspergillus spp [85, 86].   
6. Zygomycosis 
Zygomycosis is an infection caused by fungi in the orders Mucorales and 
Entomophthorales. The Mucorales order contains 2 families exist—Mucoraceae and 
Cunninghamellaceae. Mucormycosis is another common name applied to this same group 
of diseases. This designation reflected the predominance of the Mucorales in causing disease 
in humans. However, this term ignored the role of the Entomophthorales (Conidiobolus 
species and Basidiobolus species). The currently accepted designation is zygomycosis, 
reflecting all disease processes caused by the members of the class Zygomycetes. During the 
past decade, the Zygomycetes have emerged as common causes of invasive fungal 
infections [87].   
The pathogens that cause zygomycosis are commonly found in the environment on fruit, on 
bread, and in soil and are common components of decaying organic debris. These organisms 
are ubiquitous and generally saprophytic, rarely causing disease in immunocompetent 
hosts, but they are the third-most-common cause of invasive fungal infection in 
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immunocompromised patients, especially stem cell transplant recipients and patients with 
underlying hematologic malignancies [88].   
Fungi are ubiquitous in the natural world, often found in association with plants, mammals, 
and insects. Accordingly, humans are continually exposed to multiple genera of fungi via 
various routes, including the respiratory and gastrointestinal routes, which allow the 
possibility of colonization. Depending on the interaction between host mucosal defense 
mechanisms and fungal virulence factors, colonization may be transient or persistent, or 
local disease may ensue [89].    
Overall, Rhizopus species from the Mucoraceae family are the most commonly identified 
etiologic agents of zygomycosis in humans. Of the Rhizopus species, the most common agent 
associated with zygomycosis is Rhizopus arrhizus (Rhizopus oryzae), followed by Rhizopus 
rhizopodiformis. Other causes include Mucor species, Cunninghamella bertholletiae, 
Apophysomyces elegans, Absidia species, Saksenaea species, Rhizomucor pusillus, Entomophthora 
species, Conidiobolus species, and Basidiobolus species [90].    
Zygomycosis caused by R arrhizus is acute and rapidly fatal despite early diagnosis and 
treatment. These organisms have a particular predilection for invading major blood vessels, 
with ensuing ischemia, necrosis, and infarction of adjacent tissues, resulting in the 
production of black pus. Persons at particular risk include those with granulocytopenia and 
acidosis. For unknown reasons, the Zygomycetes have a propensity to affect patients with 
acidosis, particularly those with diabetes. They also infect patients with acidosis secondary 
to renal insufficiency, diarrhea, and aspirin intake. Patients who are receiving 
glucocorticoids or deferoxamine and those who have undergone splenectomy also are at 
risk [90].    
The overall mortality rate associated with zygomycosis is approximately 50% and has 
remained at this level for the past 50 years. Rhinocerebral zygomycosis carries a mortality 
rate of approximately 85%. Mortality rates are very high because, by the time zygomycosis 
is suspected and diagnosed, it has frequently spread diffusely and caused extensive tissue 
destruction. However, the risk of mortality varies depending on the characteristics of the 
host, the type of infection, the site of infection, and the use of surgical intervention. In 
general, antifungal therapy and surgical management independently decrease the likelihood 
of death [91].    
Zygomycosis manifests as a spectrum of diseases, depending on the portal of entry and the 
predisposing risk factors of the patient. The 5 major clinical forms include rhinocerebral 
zygomycosis, pulmonary zygomycosis, abdominopelvic and gastric (gastrointestinal) 
zygomycosis, primary cutaneous zygomycosis, and disseminated zygomycosis [91].     
Most persons who develop zygomycosis are immunocompromised, although 15-20% of 
patients have no evidence of any underlying condition at the time of the diagnosis.Thus, 
sporadic cases in immunocompetent hosts are not uncommon. The most common risk 
factors include the following  [91, 92] : 
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• Stem cell transplantation 
• Poorly controlled diabetes mellitus, either type 1 or type 2 
• Hematologic malignancy (eg, leukemias, lymphomas) 
• Solid organ transplants 
• Steroid use 
• Metabolic acidosis 
• Deferoxamine therapy 
• Severe and prolonged neutropenia 
• Intravenous drug use 
• Renal failure 
• Peritoneal dialysis 
• Burns 
• Penetrating trauma (rare) 
Unfortunately, findings from laboratory studies are nonspecific for zygomycosis. 
Diagnosis requires a high index of suspicion, a host with appropriate risk factors, and 
evidence of tissue invasion with the characteristic appearance of broad nonseptate hyphae 
with right-angle branches. No serologic tests are available, and blood cultures are of no 
benefit [93].  
7. Conclusion 
Opportunistic fungal infections of the body which occur almost exclusively in debilitated 
patients whose normal defence mechanisms are impaired. The organisms involved are 
cosmopolitan fungi which have a very low inherent virulence. The increased incidence of 
these infections and the diversity of fungi causing them, has paralleled the emergence of 
Acquired Immune Deficiency Syndrome (AIDS), more aggressive cancer and post-
transplantation chemotherapy and the use of antibiotics, cytotoxins, 
immunosuppressives, corticosteroids and other macro disruptive procedures that result 
in lowered resistance of the host allowing fungi to invade tissues and produce 
pathological changes that can cause death. Compromised immunity is the most 
important predisposing factor for clinically significant fungal infections. Neutrophil 
deficiency as a result of bone marrow suppression or damage is frequently associated 
with such infections. Different fungi infect humans and may live in extracellular tissues 
and within phagocytes. Therefore, the immune responses to these microbes are often 
combinations of the responses to extracellular and intracellular bacteria. However, less is 
known about antifungal immunity than about immunity against bacteria and viruses. 
This lack of knowledge is partly due to the paucity of animal models for mycoses and 
partly due to the fact that these infections typically occur in individuals who are 
incapable of mounting effective immune responses. Improved diagnostic methods have 
been developed for an early diagnostic of opportunistic mycosis in order to control the 
disease and save more lives. 
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